Table 3.
Summary of efficacya.
| | IPH5201 | IPH5201 + durvalumab 1,500 mg | Total (N = 57) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 100 mg (n = 3) |
300 mg (n = 3) |
1,000 mg (n = 13) |
3,000 mg (n = 19) |
Total (N = 38) |
300 mg (n = 4) |
1,000 mg (n = 8) |
3,000 mg (n = 7) |
Total (N = 19) |
||
| BOR, n (%) | | | | | | | | | | |
| SD | 3 (100) | 1 (33.3) | 8 (61.5) | 6 (31.6) | 18 (47.4) | 2 (50.0) | 0 | 3 (42.9) | 5 (26.3) | 23 (40.4) |
| PD | 0 | 2 (66.7) | 5 (38.5) | 11 (57.9) | 18 (47.4) | 2 (50.0) | 8 (100) | 3 (42.9) | 13 (68.4) | 31 (54.4) |
| NE | 0 | 0 | 0 | 2 (10.5) | 2 (5.3) | 0 | 0 | 1 (14.3) | 1 (5.3) | 3 (5.3) |
| Disease control ≥12 weeks, n (%) | 3 (100) | 1 (33.3) | 6 (46.2) | 4 (21.1) | 14 (36.8) | 2 (50.0) | 0 | 3 (42.9) | 5 (26.3) | 19 (33.3) |
| Median PFS, months (95% CI) | NC (4.1–NC) |
1.3 (1.3–NC) |
2.5 (1.3–5.3) |
1.4 (1.3–2.8) |
2.4 (1.4–3.5) |
6.9 (1.4–NC) |
1.3 (0.8–1.4) |
1.4 (0.7–6.2) |
1.4 (1.3–1.4) |
1.4 (1.4–2.5) |
| Median OS, months (95% CI) | 12.5 (9.8–NC) |
13.1 (1.6–NC) |
8.2 (4.4–8.7) |
7.0 (4.3–11.2) |
7.8 (5.9–10.9) |
NC (2.1–NC) |
4.2 (2.7–NC) |
11.2 (1.0–NC) |
9.2 (3.0–NC) |
8.2 (5.9–10.3) |
Abbreviations: BOR, best overall response; CI, confidence interval; NC, not calculated; NE, not evaluable; PD, progressive disease; SD, stable disease.
a
Data are shown based on the as-treated population, defined as all patients who received any investigational product.